Sunstone LSV Fund II portfolio company Anergis, a company developing proprietary ultra-fast allergy immunotherapy, announced today that it has completed patient recruitment in the ATIBAR trial, a Phase IIb field-based clinical trial with Anergis’ lead compound AllerT for patients with birch pollen allergy.
The post Anergis Completes Patient Recruitment in Large-Scale ATIBAR Trial with Ultra-Fast Allergy Immunotherapy AllerT appeared first on Sunstone.